Citations

Clear

421 citation(s) found for "Short, C".

Short Telomeres: Cause and Consequence in Liver Disease
Simonetto, Douglas A. , Penrice, Daniel D. , Simonetto, Douglas A

Mayo Clinic

Seminars in Liver Disease | June 11, 2020 | Volume: 40 | Issue: 04 | Pages: 385-391

10.1055/s-0040-1713007 | PMID 32526789 Get It

AbstractShort telomere syndrome is a genetically inherited syndrome resulting in premature telomere shortening. This premature shortening of telomeres can result in hematologic, pulmonary, vascular, gastrointestinal, and hepatic manifestations of disease. Identifying patients with short telomere syndrome can be a clinical challenge due to the multitude of potential manifestations and lack of widely available diagnostic tests. In this review, we will highlight hepatic manifestations of short telomere syndrome with a focus on diagnosis, testing, and potential treatments.
Guidance on Short‐Term Management of Atrial Fibrillation in Coronavirus Disease 2019
Rattanawong, Pattara , Shen, Win K., Masry, Hicham El , Sorajja, Dan , Srivathsan, Komandoor , Valverde, Arturo M. , Scott, Luis R. , Shen, Win, El Masry, Hicham, Valverde, Arturo, Rattanawong, Pattara , El Masry, Hicham , Srivathsan, Komandoor , Valverde, Arturo M

Mayo Clinic

Journal of the American Heart Association | June 9, 2020 | Volume: 9 | Issue: 14 | Pages: No page available

10.1161/jaha.120.017529 | PMID 32515253 Get It

Abstract Atrial fibrillation is a common clinical manifestation in hospitalized patients with coronavirus disease 2019 (COVID‐19). Medications used to treat atrial fibrillation, such as antiarrhythmic drugs and anticoagulants, may have significant drug interactions with emerging COVID‐19 treatments. Common unintended nontherapeutic target effects of COVID‐19 treatment include potassium channel blockade, cytochrome P 450 isoenzyme inhibition or activation, and P‐glycoprotein inhibition. Drug‐drug interactions with antiarrhythmic drugs and anticoagulants in these patients may lead to significant bradycardia, ventricular arrhythmias, or severe bleeding. It is important for clinicians to be aware of these interactions, drug metabolism changes, and clinical consequences when choosing antiarrhythmic drugs and anticoagulants for COVID‐19 patients with atrial fibrillation. The objective of this review is to provide a practical guide for clinicians who are managing COVID‐19 patients with concomitant atrial fibrillation.
Genomic Analysis of Historical Cases with Positive Newborn Screens for Short-Chain Acyl-CoA Dehydrogenase Deficiency Shows That a Validated Second-Tier Biochemical Test Can Replace Future Sequencing
Adhikari, Aashish N. , Currier, Robert J. , Tang, Hao , Turgeon, Coleman , Nussbaum, Robert L. , Srinivasan, Rajgopal, Sunderam, Uma, Brenner, Steven E. , Gavrilov, Dimitar , Puck, Jennifer M. , Gallagher, Renata C. , Nussbaum, Robert , Turgeon, Coleman T, Currier, Robert , Kwok, Pui–Yan

Mayo Clinic

International Journal of Neonatal Screening | May 27, 2020 | Volume: 6 | Issue: 2 | Pages: 41

10.3390/ijns6020041 | PMID 32802992 Get It

Short-chain acyl-CoA dehydrogenase deficiency (SCADD) is a rare autosomal recessive disorder of β-oxidation caused by pathogenic variants in the ACADS gene. Analyte testing for SCADD in blood and urine, including newborn screening (NBS) using tandem mass spectrometry (MS/MS) on dried blood spots (DBSs), is complicated by the presence of two relatively common ACADS variants (c.625G>A and c.511C>T). Individuals homozygous for these variants or compound heterozygous do not have clinical disease but do have reduced short-chain acyl-CoA dehydrogenase (SCAD) activity, resulting in elevated blood and urine metabolites. As part of a larger study of the potential role of exome sequencing in NBS in California, we reviewed ACADS sequence and MS/MS data from DBSs from a cohort of 74 patients identified to have SCADD. Of this cohort, approximately 60% had one or more of the common variants and did not have the two rare variants, and thus would need no further testing. Retrospective analysis of ethylmalonic acid, glutaric acid, 2-hydroxyglutaric acid, 3-hydroxyglutaric acid, and methylsuccinic acid demonstrated that second-tier testing applied before the release of the newborn screening result could reduce referrals by over 50% and improve the positive predictive value for SCADD to above 75%.
Short-term adjuvant versus neoadjuvant hormone therapy in localized prostate cancer: A pooled individual patient analysis of two phase III trials.
Malone, Shawn , Roy, Soumyajit , Grimes, Scott, Eapen, Libni , Malone, Julia, Craig, Julia , Dess, Robert T. , Schipper, Matthew J. , Michalski, Jeff M. , Pisansky, Thomas M. , Feng, Felix Y. , Shipley, William U. , Roach, Mack , Lawton, C.A., Dess, Robert T , Spratt, Daniel E. , Morgan, Scott C. , Jackson, Will , Lee, W. Robert , Sandler, Howard M. , Sun, Yilun

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 5584-5584

10.1200/jco.2020.38.15_suppl.5584 Get It

5584 Background: The timing of systemic therapy in relation to radiotherapy (RT) is important in most malignancies. In contrast, androgen deprivation therapy (ADT) has largely been investigated in relation to its duration rather than its sequencing with RT. Herein, we conduct the first combined individual patient analysis of two phase III randomized trials to determine the optimal timing of ADT with RT in localized prostate cancer (PCa). Methods: Individual patient data was obtained from the Malone et al trial (JCO 2019), which randomized patients to receive neoadjuvant/concurrent or concurrent/adjuvant ADT for 6 months with prostate only RT. This was combined with the prostate only RT arms of RTOG 9413 that randomized patients to 4 months of neoadjuvant/concurrent or adjuvant ADT. The neoadjuvant/concurrent arms of both trials were combined into the “neoadjuvant” group, and the concurrent/adjuvant (Malone) and adjuvant arm (RTOG 9413) were combined in the “adjuvant” group. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Cumulative incidence of distant metastasis (DM), PCa-specific mortality (PCSM) and biochemical failure (BF) were calculated using the Fine-Gray method with non-PCa deaths as competing events. Late genitourinary (GU) and gastrointestinal (GI) toxicity are also reported. Results: The median follow-up was 14.9 years (yrs) and 1065 patients were included (n=531 neoadjuvant, 534 adjuvant). Groups were well balanced for all baseline characteristics. Adjuvant ADT was superior to neoadjuvant ADT in terms of BF (15yr: 33% vs 43%, HR: 1.37 (95%CI: 1.12-1.68), p=0.002), DM (15yr: 12% vs 18%, HR: 1.40 (95%CI: 1.00-1.95), p=0.04), and PFS (15yr: 36% vs 29%, HR: 1.25 (95%CI: 1.07-1.47), p=0.01). Adjuvant ADT yielded lower PCSM (15yr: 15% vs 20%, HR: 1.29 (95%CI: 0.95-1.75), p=0.10), but did not reach statistical significance. This approached statistical significance in high risk PCa (HR 1.39 (95%CI 1.00-1.93), p=0.053). OS was not significantly different between arms (15yr: 39% vs 34%, HR: 1.11 (95%CI: 0.95-1.30), p=0.20). There was no significant difference in either late grade ≥3 GI (p=0.21) or GU (p=0.98) toxicity. Conclusions: We demonstrate for the first time that sequencing of ADT with RT significantly impacts long-term oncologic outcomes in localized PCa, favoring an adjuvant rather than neoadjuvant approach, without increasing late toxicity. This data has important implications to ongoing and future clinical trial design. Clinical trial information: NCT00769548 .
Perilunate Injury with Concomitant Short Radiolunate Ligament Disruption: Prevalence and Surgical Outcomes—"An Unusual Perilunate Injury Variant”
Sgromolo, Nicole M., Mullikin, Ian , Rhee, Peter C. , Mullikin, Ian A

Mayo Clinic

Journal of Wrist Surgery | May 20, 2020 | Volume: 09 | Issue: 04 | Pages: 312-320

10.1055/s-0040-1710396 | PMID 32760610 Get It

Abstract Background In the classic description of perilunate injuries, the short radiolunate ligament (SRL) remains intact. Objective This study was aimed to determine the occurrence of SRL disruptions with perilunate injuries and review the clinical and radiographic outcomes after surgical management. Patients and Methods A retrospective review was conducted for patients who sustained a perilunate injury and a concomitant disruption of the SRL at a single–level-1 trauma center between January 2013 and January 2017. Patients with the combined injury pattern were compared with those with perilunate injury alone without SRL injury during the study period. Outcome measures included pain scores (visual analogue score), wrist and forearm range of motion, patient's return to their former occupation, and multiple radiographic parameters. Results Twenty-seven patients were treated operatively for a perilunate injury. Eight of these patients (30%) were found to have associated disruption of the SRL. When compared with patients with perilunate injury alone, these patients had a lower rate of return to work (57% [4 of 7] vs. 92% [12 of 13]), a significantly longer mean length of time to return to work (5.9 vs. 3.8 months), and a higher rate of associated upper extremity injury (75% [3 of 8] vs. 16% [3 of 19]. Conclusion Combined SRL disruption and perilunate dislocation or fracture dislocation represent a high-energy variant from the classic description of a perilunate injury. A heightened awareness for this combined injury pattern should be maintained when treating patients with perilunate injuries. Level of Evidence This is a Level III, prognostic study.
Efficient targeted integration directed by short homology in zebrafish and mammalian cells
Wierson, Wesley A. , Welker, Jordan M. , Almeida, Maira P. , Mann, Carla M. , Webster, Dennis A., Torrie, Melanie E., Kambakam, Sekhar , Vollbrecht, Macy , Lan, Merrina, McKeighan, Kenna C, Levey, Jacklyn , Ming, Zhitao, Wehmeier, Alec, Mikelson, Christopher S, Haltom, Jeffrey , Kwan, Kristen M. , Chien, Chi‐Bin, Balciunas, Darius , Ekker, Stephen C. , Webber, Beau R. , Moriarity, Branden S. , Solin, Stacy L, McGrail, Maura , Kwan, Kristen M , Balciunas, Darius , Ekker, Stephen C , Clark, Karl J , McGrail, Maura , Essner, Jeffrey , Webber, Beau R , Weiss, Trevor J. , Chien, Chi-Bin, Clark, Karl J. , Carlson, Daniel F. , Dobbs, Drena L , Essner, Jeffrey J.

Mayo Clinic

eLife | May 15, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.53968 | PMID 32412410 Get It

Efficient precision genome engineering requires high frequency and specificity of integration at the genomic target site. Here, we describe a set of resources to streamline reporter gene knock-ins in zebrafish and demonstrate the broader utility of the method in mammalian cells. Our approach uses short homology of 24–48 bp to drive targeted integration of DNA reporter cassettes by homology-mediated end joining (HMEJ) at high frequency at a double strand break in the targeted gene. Our vector series, pGTag (plasmids for Gene Tagging), contains reporters flanked by a universal CRISPR sgRNA sequence which enables in vivo liberation of the homology arms. We observed high rates of germline transmission (22–100%) for targeted knock-ins at eight zebrafish loci and efficient integration at safe harbor loci in porcine and human cells. Our system provides a straightforward and cost-effective approach for high efficiency gene targeting applications in CRISPR and TALEN compatible systems.
Faculty Opinions recommendation of Determinants of Cyclization-Decyclization Kinetics of Short DNA With Sticky Ends.
Maher, Jim

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 27, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.737741438.793573634 Get It

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, Patrick Y. , Weller, Michael , Lee, Eudocia Q. , Barnholtz‐Sloan, Jill S. , Barthel, Floris P , Batchelor, Tracy T. , Chang, Susan M. , DeGroot, John, Hegi, Monika E. , Huang, Raymond Y. , Lassman, Andrew B. , Lim, Michael , Mellinghoff, Ingo K. , Minniti, Giuseppe , Nathanson, David A. , Platten, Michael , Preusser, Matthias , Roth, Patrick , Sanson, Marc , Schiff, David , Short, Susan , Taphoorn, Martin , Tonn, Joerg-Christian, Tsang, Jonathan , Verhaak, Roel G.W. , Deimling, Andreas von , Zadeh, Gelareh , Reardon, David A. , Aldape, Kenneth , Bent, Martin J. van den , Weller, Michael , Short, Susan C , van den Bent, Martin J , Barnholtz-Sloan, Jill S , Platten, Michael , Preusser, Matthias , Sanson, Marc , von Deimling, Andreas , Mellinghoff, Ingo K , Huang, Raymond , Roth, Patrick , Barthel, Floris P , Wen, Patrick Yung , Alexander, Brian M. , Bindra, Ranjit S. , Chiocca, E Antonio , Cloughesy, Timothy F. , Galanis, Evanthia , Gilbert, Mark R. , Horbinski, Craig , Rhun, Émilie Le , Mehta, Minesh P. , Tonn, Joerg-Christian , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology | April 20, 2020 | Volume: 22 | Issue: 8 | Pages: 1073-1113

10.1093/neuonc/noaa106 | PMID 32328653 Get It

Abstract Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.